A Randomized Study of the Site for Growth Factor Injection for Patients Undergoing Autologous Stem Cell Transplantation
NCT00646763 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35
Last updated 2025-04-01
Summary
The purpose of this study is to determine whether or not the injection site of cytokines, or growth factors, has an effect on peripheral blood stem cell collection.
Conditions
- Cytokines
Interventions
- DRUG
-
G-CSF, GM-CSF administered at extremities
Injection site Extremities: G-CSF injections will commence on the day after completion of mobilization chemotherapy, at least 24 hours after completion of the last chemotherapy dose. On the seventh day of cytokine administration, GMCSF injections will be started, and patients will maintain a twice daily schedule of G-CSF/GM-CSF until stem cell collection is complete.
- DRUG
-
G-CSF and GMCSF administered at abdomen
Injection site Abdomen: G-CSF injections will commence on the day after completion of mobilization chemotherapy, at least 24 hours after completion of the last chemotherapy dose. On the seventh day of cytokine administration, GMCSF injections will be started, and patients will maintain a BID schedule of G-CSF/GM-CSF until stem cell collection is complete.
Sponsors & Collaborators
-
Emory University
lead OTHER
Principal Investigators
-
Edmund Waller, MD · Emory University Winship Cancer Institute
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2008-04-30
- Primary Completion
- 2009-09-30
- Completion
- 2011-02-28
Countries
- United States
Study Locations
More Related Trials
-
Evaluating Clinical Evaluation Tools for Predicting Risk of Complications After Hematopoietic Stem Cell Transplant
NCT05766332 ·Status: COMPLETED
-
The Optimization of Haploidentical Hematopoietic Stem Cell Transplantation
NCT05629260 ·Status: RECRUITING
-
Study of Low-Intensity Conditioning for Allogeneic Stem Cell Transplant
NCT00143845 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies
NCT06294678 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Intraosseous Administration of Mesenchymal Stromal Cells for Patients With Graft Failure After Allo-HSCT
NCT03389919 ·Status: UNKNOWN ·Phase: PHASE3
-
Remote Ischemic Conditioning in HSCT
NCT04808167 ·Status: COMPLETED ·Phase: NA
-
Interindividual Genetic Variability as a Determinant of Chemotherapy Toxicity and Response in Pediatric Bone Marrow Transplantation Patients
NCT00578630 ·Status: COMPLETED
-
Injection of ex Vivo Amplified G-CSF Mobilised Autologous Peripheral Blood Stem Cell Transplantation
NCT00461955 ·Status: COMPLETED ·Phase: PHASE2
-
Unrelated Donor Stem Cell Transplantation
NCT01364363 ·Status: COMPLETED ·Phase: NA
-
Effect of Stem Cell Infusion Time on aGVHD in Patients With Nonmalignant Hematologic Diseases
NCT06294691 ·Status: RECRUITING ·Phase: PHASE3
-
Hemostatic Complications in Hematopoietic Stem Cell Transplantation
NCT02281240 ·Status: UNKNOWN
-
Study of Low Intensity Conditioning and Immunotherapy for High-Risk Cancers of the Blood
NCT00143884 ·Status: TERMINATED ·Phase: PHASE2
-
Physiologic Effects of RBC Transfusion
NCT02566577 ·Status: TERMINATED ·Phase: PHASE4
-
Safety and Efficacy Study of Umbilical Cord Blood-Drived Mesenchymal Stem Cells to Promote Engraftment of Unrelated Hematopoietic Stem Cell Transplantation
NCT00823316 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Prophylaxis Roles of IL-2 Treatment on GVHD After Transplantation
NCT02659657 ·Status: UNKNOWN ·Phase: PHASE2
-
A Phase 2 Study of Home Care Following Autologous Hematopoietic Stem Cell Transplantation
NCT03667599 ·Status: RECRUITING ·Phase: NA
-
The Value of Peripheral Blood CD34+ Cell Dynamics Monitoring in Autologous Hematopoietic Stem Cell Transplant Mobilization
NCT05970185 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
Expansion of Invariant NKT Cells for a Cell Immunotherapeutic Approach Allowing the Control of Graft Versus Host-disease and Preserving the Graft Versus Leukemia Effect After Allogeneic Hematopoietic Stem Cell Transplantation
NCT03605953 ·Status: UNKNOWN
-
Exploring the Mechanisms of Resistance of Stem Cells Myeloproliferative Opposite of Tyrosine Kinase Inhibitors in 3d Model Niche Endosteal
NCT02766153 ·Status: TERMINATED
-
Protocol for a Research Sample Repository for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries
NCT04920474 ·Status: RECRUITING
-
Donor Mesenchymal Stem Cell Infusion in Treating Patients With Acute or Chronic Graft-Versus-Host Disease After Undergoing a Donor Stem Cell Transplant
NCT00361049 ·Status: COMPLETED ·Phase: PHASE1
-
Recombinant Human Interleukin-7 (CYT107) to Promote T-Cell Recovery After Cord Blood Transplantation
NCT03600896 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Autologous Stem Cells for Spinal Cord Injury (SCI) in Children
NCT01328860 ·Status: TERMINATED ·Phase: PHASE1
-
Risk Stratification-directed NAC for Prevention of Poor Hematopoietic Reconstitution
NCT03967665 ·Status: UNKNOWN ·Phase: PHASE3
-
Feasibility of Collecting Quality of Life Data in Collaboration With the Stem Cell Therapeutic Outcomes Database
NCT01353677 ·Status: COMPLETED